Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of Directors. With a distinguished career of 30 years in the biopharmaceutical industry, Mr. Civik has extensive experience in bringing oncology innovations to patients and from executive leadership roles, most recently as CEO of Five Prime Therapeutics. He will join ImCheck’s Board as the company further develops its lead program ICT01 and a range of antibody therapeutics targeting butyrophilins, a novel super-family of immunomodulators. Dr. Debasish Roychowdhury, Chairman since 2018, will step down from the Board and remain an advisor to the company. En savoir plus
